Carregant...
Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline
BACKGROUND: This systematic review addresses the question “What is the optimal targeted therapy for female patients with early-stage human epidermal growth factor receptor 2 (her2)–positive breast cancer?” METHODS: The medline and embase databases were searched for the period January 2008 to May 201...
Guardat en:
| Publicat a: | Curr Oncol |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Multimed Inc.
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4381787/ https://ncbi.nlm.nih.gov/pubmed/25848335 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.22.2322 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|